Clinical and molecular aspects of multiple endocrine neoplasia

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The discovery that RET proto-oncogene mutations are responsible for MEN2 and FMTC was a landmark from the perspective of many, including the geneticist involved in basic science, the molecular diagnostician, the clinician, and MEN2/FMTC families. The discovery has provided basic information concerning the role of proto-oncogenes and proto-oncogene activation. The identification of MEN2/FMTC-associated mutations has also allowed for the availability of direct mutation analysis in the routine clinical laboratory. The discovery has resulted in definitive risk assessment for members of FMTC/MEN2 kindreds and improved management of RET mutation carriers. The discovery also links two realms of genetics that are often separated: cancer genetics and 'classic' mendelian disorders. Finally, information concerning the molecular basis of Hirschsprung disease indicates that our understanding of the phenotypic consequences of RET mutations is considerable but not yet complete.

Original languageEnglish (US)
Pages (from-to)39-57
Number of pages19
JournalClinics in Laboratory Medicine
Volume17
Issue number1
StatePublished - 1997
Externally publishedYes

Fingerprint

Multiple Endocrine Neoplasia
Clinical laboratories
Proto-Oncogenes
Mutation
Risk assessment
Chemical activation
Availability
Hirschsprung Disease
Genetics
Neoplasms

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Clinical and molecular aspects of multiple endocrine neoplasia. / Wick, Myra J.

In: Clinics in Laboratory Medicine, Vol. 17, No. 1, 1997, p. 39-57.

Research output: Contribution to journalArticle

@article{e01067fbd3d7471b83cff159934ae4de,
title = "Clinical and molecular aspects of multiple endocrine neoplasia",
abstract = "The discovery that RET proto-oncogene mutations are responsible for MEN2 and FMTC was a landmark from the perspective of many, including the geneticist involved in basic science, the molecular diagnostician, the clinician, and MEN2/FMTC families. The discovery has provided basic information concerning the role of proto-oncogenes and proto-oncogene activation. The identification of MEN2/FMTC-associated mutations has also allowed for the availability of direct mutation analysis in the routine clinical laboratory. The discovery has resulted in definitive risk assessment for members of FMTC/MEN2 kindreds and improved management of RET mutation carriers. The discovery also links two realms of genetics that are often separated: cancer genetics and 'classic' mendelian disorders. Finally, information concerning the molecular basis of Hirschsprung disease indicates that our understanding of the phenotypic consequences of RET mutations is considerable but not yet complete.",
author = "Wick, {Myra J}",
year = "1997",
language = "English (US)",
volume = "17",
pages = "39--57",
journal = "Clinics in Laboratory Medicine",
issn = "0272-2712",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Clinical and molecular aspects of multiple endocrine neoplasia

AU - Wick, Myra J

PY - 1997

Y1 - 1997

N2 - The discovery that RET proto-oncogene mutations are responsible for MEN2 and FMTC was a landmark from the perspective of many, including the geneticist involved in basic science, the molecular diagnostician, the clinician, and MEN2/FMTC families. The discovery has provided basic information concerning the role of proto-oncogenes and proto-oncogene activation. The identification of MEN2/FMTC-associated mutations has also allowed for the availability of direct mutation analysis in the routine clinical laboratory. The discovery has resulted in definitive risk assessment for members of FMTC/MEN2 kindreds and improved management of RET mutation carriers. The discovery also links two realms of genetics that are often separated: cancer genetics and 'classic' mendelian disorders. Finally, information concerning the molecular basis of Hirschsprung disease indicates that our understanding of the phenotypic consequences of RET mutations is considerable but not yet complete.

AB - The discovery that RET proto-oncogene mutations are responsible for MEN2 and FMTC was a landmark from the perspective of many, including the geneticist involved in basic science, the molecular diagnostician, the clinician, and MEN2/FMTC families. The discovery has provided basic information concerning the role of proto-oncogenes and proto-oncogene activation. The identification of MEN2/FMTC-associated mutations has also allowed for the availability of direct mutation analysis in the routine clinical laboratory. The discovery has resulted in definitive risk assessment for members of FMTC/MEN2 kindreds and improved management of RET mutation carriers. The discovery also links two realms of genetics that are often separated: cancer genetics and 'classic' mendelian disorders. Finally, information concerning the molecular basis of Hirschsprung disease indicates that our understanding of the phenotypic consequences of RET mutations is considerable but not yet complete.

UR - http://www.scopus.com/inward/record.url?scp=0030943305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030943305&partnerID=8YFLogxK

M3 - Article

C2 - 9138898

AN - SCOPUS:0030943305

VL - 17

SP - 39

EP - 57

JO - Clinics in Laboratory Medicine

JF - Clinics in Laboratory Medicine

SN - 0272-2712

IS - 1

ER -